Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H19NO.C7H6O2 |
| Molecular Weight | 363.4495 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1.C(OC2CCNCC2)C3=CC=C4C=CC=CC4=C3
InChI
InChIKey=XALIHSKERZFMMK-UHFFFAOYSA-N
InChI=1S/C16H19NO.C7H6O2/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16;8-7(9)6-4-2-1-3-5-6/h1-6,11,16-17H,7-10,12H2;1-5H,(H,8,9)
Litoxetine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and mixed serotonin agonist-antagonist, which makes it particularly appropriate for treating continence dysfunctions. Litoxetine at concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxations in the rat isolated oesophageal muscularis mucosae, which reduced carbachol tone up to 37%. Higher litoxetine concentrations (3 microM-300 microM) were associated with marked relaxation up to the abolition of carbachol tone. The antimuscarinic activity of litoxetine, previously demonstrated in the isolated guinea-pig intestine, played a role in the rat isolated oesophageal muscularis mucosae at concentrations greater than 1 microM. The 5-HT-releasing action of litoxetine could account for the potentation by litoxetine of 5-HT-induced relaxation in tissues from untreated rats, which was reversed by pCPA treatment. Litoxetine is in phase II clinical trial for the treatment of urinary incontinence.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. | 2009-10-15 |
|
| Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. | 2009-04-15 |
|
| Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. | 2002-04 |
|
| Influence of fluoxetine and litoxetine on 5-HT4 receptor-mediated relaxation in the rat isolated oesophagus. | 1999 |
|
| Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter. | 1996-05-03 |
|
| The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers. | 1995-08 |
|
| The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. | 1995-03 |
|
| EEG profile of litoxetine after single and repeated administration in healthy volunteers. | 1994-02 |
|
| Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. | 1993-03-02 |
|
| Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. | 1992-05 |
|
| Advances in sodium-ion coupled biogenic amine transporters. | 1992 |
|
| A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter. | 1989-11-01 |
|
| Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro. | 1988 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
169490723
Created by
admin on Wed Apr 02 00:27:50 GMT 2025 , Edited by admin on Wed Apr 02 00:27:50 GMT 2025
|
PRIMARY | |||
|
3N6AFA37Y3
Created by
admin on Wed Apr 02 00:27:50 GMT 2025 , Edited by admin on Wed Apr 02 00:27:50 GMT 2025
|
PRIMARY | |||
|
125335-37-7
Created by
admin on Wed Apr 02 00:27:50 GMT 2025 , Edited by admin on Wed Apr 02 00:27:50 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
